1-3 of 3
L. Leanne Lash
Close
Sort by
Journal Articles

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis
Journal: Blood
Blood (2021) 138 (Supplement 1): 817.
https://doi.org/10.1182/blood-2021-146043
Published: 2021
Journal Articles

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

William G Wierda, MD PhD, John F Seymour, MBBS, PhD, Andrew W. Roberts, Su Young Kim, L. Leanne Lash-Fleming, Johnathan Maher, Todd Busman, Lang Zhou, Jacqueline Nielsen, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4329.
https://doi.org/10.1182/blood.V130.Suppl_1.4329.4329
Published: 2017
Journal Articles

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Danielle M. Brander, MD, Michael Y. Choi, MD, Andrew W. Roberts, Shuo Ma, L. Leanne Lash, Maria Verdugo, Ming Zhu, Su Young Kim, John F Seymour
Journal: Blood
Blood (2016) 128 (22): 2033.
https://doi.org/10.1182/blood.V128.22.2033.2033
Published: 2016